The French Competition Authority fines three laboratories for abusive practices (Novartis / Roche / Genentech)

Treatment for AMD: the Autorité fines 3 laboratories for abusive practices* The Autorité de la concurrence has imposed fines worth a total of €444 million on three pharmaceutical companies, Novartis, Roche and Genentech, for abusive practices designed to sustain the sales of Lucentis for AMD treatment to the detriment of Avastin (a competitive medicinal product that is 30 times cheaper). Background Age-related macular degeneration (AMD) is the main cause of low vision for people over 50 in industrialized countries. It causes severe impairment of central vision, which is particularly present in the form of dark spots perceived by the patient in the middle of its vision. The Genentech laboratory has developed a drug, Lucentis, to treat AMD. It also developed another medicine, an

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority fines three laboratories for abusive practices (Novartis / Roche / Genentech), 9 September 2020, e-Competitions September 2020, Art. N° 96662

Visites 447

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues